VYGR250117C7500
- 0.10
- +0.02+25.00%
Voyager Therapeutics Newsroom
Voyager Therapeutics Analyst Ratings
Citi Initiates Voyager Therapeutics(VYGR.US) With Buy Rating, Announces Target Price $12
Wedbush Upgrades Voyager Therapeutics(VYGR.US) to Buy Rating, Announces Target Price $11
Voyager Therapeutics Is Maintained at Buy by Canaccord Genuity
Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)
A Quick Look at Today's Ratings for Voyager Therapeutics(VYGR.US), With a Forecast Between $14 to $30
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Wells Fargo Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $14
TD Cowen Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (VYGR), Align Tech (ALGN) and Cigna (CI)
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
TD Cowen Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $30
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $14
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating
Voyager Therapeutics Analyst Ratings
Leerink Partners Initiates Voyager Therapeutics(VYGR.US) With Buy Rating, Announces Target Price $15
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18